Iontophoresis-assisted corneal crosslinking using 0.1% riboflavin for progressive keratoconus

Jia, Hong-Zhen; Pang, Xu; Fan, Zhengjun; Li, Na; Li, Gang; Peng, Xueping

doi:10.18240/ijo.2017.05.09

Cited by 7 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small current of 1 mA is then applied for 5 min. Once adequate stromal soakage by riboflavin is confirmed through slit-lamp examination, the cornea is then irradiated with UV-A light ( 135 , 136 ).…”

Section: Surgical Treatmentmentioning

confidence: 99%

Management of keratoconus: an updated review

et al. 2023

View full text Add to dashboard Cite

Keratoconus is the most common corneal ectatic disorder. It is characterized by progressive corneal thinning with resultant irregular astigmatism and myopia. Its prevalence has been estimated at 1:375 to 1:2,000 people globally, with a considerably higher rate in the younger populations. Over the past two decades, there was a paradigm shift in the management of keratoconus. The treatment has expanded significantly from conservative management (e.g., spectacles and contact lenses wear) and penetrating keratoplasty to many other therapeutic and refractive modalities, including corneal cross-linking (with various protocols/techniques), combined CXL-keratorefractive surgeries, intracorneal ring segments, anterior lamellar keratoplasty, and more recently, Bowman’s layer transplantation, stromal keratophakia, and stromal regeneration. Several recent large genome-wide association studies (GWAS) have identified important genetic mutations relevant to keratoconus, facilitating the development of potential gene therapy targeting keratoconus and halting the disease progression. In addition, attempts have been made to leverage the power of artificial intelligence-assisted algorithms in enabling earlier detection and progression prediction in keratoconus. In this review, we provide a comprehensive overview of the current and emerging treatment of keratoconus and propose a treatment algorithm for systematically guiding the management of this common clinical entity.

show abstract

Section: Surgical Treatmentmentioning

confidence: 99%

Management of keratoconus: an updated review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The first studies, designed as case series and nonrandomized small sample-sized clinical trials date back to 2014 and found decreases in average keratometry values and stabilization of uncorrected visual acuity (UCVA), corrected distance visual acuity (CDVA), corneal astigmatism, and endothelial cell density with 12 months [39-42] and 24 months [43] follow-up both in early and advanced keratoconus [20].…”

Section: Clinical Trials On Classic I-cxlmentioning

confidence: 99%

New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking

et al. 2021

View full text Add to dashboard Cite

Keratoconus is a bilateral, asymmetric and progressive corneal disease. It usually results in apical thinning and steepening with corneal deformation and impaired vision. Since the early 1990 s, corneal collagen crosslinking (CXL) has remained the primary treatment to stabilize the progression of the disease. Iontophoresis-assisted CXL (I-CXL) has been proposed as a non-invasive alternative to standard epithelium-off technique, showing promising results. In this article, we review up to date literature to provide state of art knowledge and future perspectives of I-CXL.

show abstract

“…Other studies have shown inhibition of keratoconus progression within 24 months, resulting in a significant improvement in visual and topographic parameters. Riboflavin (0.1%) was used in iontophoresis-assisted corneal crosslinking [61]. Application of riboflavin in corneal stroma by iontophoresis for halting keratoconus progression was also suggested by Mencucci et al [59].…”

Section: Vitaminsmentioning

confidence: 99%

Selected Medicines Used in Iontophoresis

Karpiński

2018

Pharmaceutics

View full text Add to dashboard Cite

Iontophoresis is a non-invasive method of systemic and local drug delivery using an electric field. Iontophoresis enables diffusion of the selected drug via skin, mucosa, enamel, dentin, and other tissues. The amount of delivered therapeutic molecules is about 10–2000 times greater than conventional forms of delivery. Among other fields, this method is used in dentistry, ophthalmology, otorhinolaryngology, and dermatology. According to related literature, the most important drugs studied or administered by iontophoresis are: Local anesthetics, opioids, steroids, non-steroidal anti-inflammatory drugs, antibacterial drugs, antifungal drugs, antiviral drugs, anticancer drugs, fluorides, and vitamins. The present review covers current available data regarding the selected medicines used in iontophoresis. Furthermore, indications and conditions of iontophoresis application are reviewed.

show abstract

Iontophoresis-assisted corneal crosslinking using 0.1% riboflavin for progressive keratoconus

Abstract: I-CXL using 0.1% riboflavin halts keratoconus progression within 24mo, resulting in a significant improvement in visual and topographic parameters. Moreover, the depth of the demarcation line is similar to that previously reported in standard epithelium-off CXL procedures.

Cited by 7 publications

References 30 publications

Management of keratoconus: an updated review

Management of keratoconus: an updated review

New perspectives in keratoconus treatment: an update on iontophoresis-assisted corneal collagen crosslinking

Selected Medicines Used in Iontophoresis

Contact Info

Product

Resources

About